Innovation deficit revisited: reflections on the productivity of pharmaceutical R&D

摘要: Abstract Consolidation continues to be a major feature of the pharmaceutical industry, largely due impact `innovation deficit'. The author performs healthcheck on industry by examining recent productivity in terms number and quality new chemical entities introduced 1996 1997. He argues that compared with an earlier projection statistical data assembled for 1993, situation appears better than was expected, however, fundamental problem innovation deficit remains.